Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.

26 August 2017 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Milan Gupta

University of Toronto, Toronto (Canada)

53 More presentations in this session

Presentation thumbnail

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

Doctor A. Tyminska (Warsaw, PL)

Abstract Slides

Presentation thumbnail

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Professor H. Bonnemeier (Luebeck, DE)

Abstract Slides

Presentation thumbnail

Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences

Ms D. Loikas (Stockholm, SE)

Abstract Slides

Presentation thumbnail

Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)

Doctor J. Franchino-Elder (Ridgefield, US)

Presentation thumbnail

Real-world single tertiary-care multidisciplinary experience with dabigatran, apixaban, rivaroxaban and warfarin in patients with renal failure and concomitant NVAF.

Doctor F. Melillo (Milan, IT)

Access the full session

Session thumbnail

Poster session 4 - Stroke prevention

The Event

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources